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Abstract
Background: Previous research has indicated that phosphatidylserine (PS) supplementation has
the potential to attenuate the serum cortisol response to acute exercise stress. Equivocal findings
suggest that this effect might be dose dependent. This study aimed to examine the influence of
short-term supplementation with a moderate dose of PS (600 mg per day) on plasma
concentrations of cortisol, lactate, growth hormone and testosterone before, during, and following
moderate intensity exercise in healthy males.
Methods: 10 healthy male subjects participated in the study. Each subject was assigned to ingest
600 mg PS or placebo per day for 10 days using a double-blind, placebo-controlled, crossover
design. Serial venous blood samples were taken at rest, after a 15 minute moderate intensity
exercise protocol on a cycle ergometer that consisted of five 3-minute incremental stages
beginning at 65% and ending at 85% VO2 max, and during a 65 minute passive recovery. Plasma
samples were assessed for cortisol, growth hormone, testosterone, lactate and testosterone to
cortisol ratio for treatment (PS or placebo).
Results: Mean peak cortisol concentrations and area under the curve (AUC) were lower following
PS (39 ± 1% and 35 ± 0%, respectively) when compared to placebo (p < 0.05). PS increased AUC
for testosterone to cortisol ratio (184 ± 5%) when compared to placebo (p < 0.05). PS and placebo
supplementation had no effect on lactate or growth hormone levels.
Conclusion: The findings suggest that PS is an effective supplement for combating exercise-
induced stress and preventing the physiological deterioration that can accompany too much
exercise. PS supplementation promotes a desired hormonal status for athletes by blunting
increases in cortisol levels.
Background
Phosphatidylserine (PS) is a naturally occurring phos-
pholipid nutrient that is most concentrated in organs with
high metabolic activity, such as the brain, lungs, heart,
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liver, and skeletal muscle. PS is located mainly in the
internal layer of the cell membrane and has a variety of
unique regulatory and structural functions. PS modulates
the activity of receptors, ion channels, enzymes and sign-
aling molecules and is involved in governing membrane
fluidity [1]. Traditionally, PS supplements were derived
from bovine cortex (BC-PS); however, due to the potential
transfer of infectious diseases, soy-derived PS (S-PS) has
been established as a safe alternative [2]. PS has been
shown to improve a variety of brain functions that tend to
decline with age [3]. In recent studies, PS has been shown
to enhance mood in a cohort of young people during
mental stress [4] and to improve accuracy during tee-off
by increasing the golfer's stress resistance [5].
An excessive cortisol response to exercise-induced stress
has been linked to a negative training state, which could
lead to overreaching or overtraining [6]. During early
stages of overtraining muscles become sore, submaximal
and resting heart rate increase and testosterone levels fall.
The body has difficulties in adjusting, but usually recovers
with a few days' rest. Chronic overtraining often creates a
disturbance in the anabolic-catabolic balance, which may
express itself in decreased performance, injury, depressed
immunity and psychological depression [7].
PS has been demonstrated to speed up recovery, prevent
muscle soreness, improve well-being, and might possess
ergogenic properties in athletes involved in cycling,
weight training and endurance running [8]. PS has been
reported to be an effective supplement for combating
exercise-induced stress and preventing the physiological
deterioration that accompanies too much exercise. BC-PS
has been reported to attenuate serum cortisol and adren-
ocorticotropic hormone (ACTH) responses to staged
cycling exercise. 800 mg BC-PS supplementation lowered
cortisol response by 30%, whereas 400 mg showed no sig-
nificant results compared to placebo [9]. Also, 800 mg S-
PS has been reported to reduce the cortisol response to
intensive resistance training by 20% [10]. PS had no effect
on testosterone levels [10]. These finding suggest that PS
partly counteracts the stress-induced activation of the
hypothalamo-pituitary-adrenal (HPA) axis [11].
Studies using less than 800 mg of S-PS supplementation
showed beneficial effects on performance and markers of
muscle damage. 750 mg of S-PS resulted in an increased
time to exhaustion during stage intermittent cycling exer-
cise [12], and tended to improve sprint and exercise per-
formances during exhaustive intermittent running when
compared to placebo [13]. 600 mg and 300 mg S-PS sig-
nificantly lowered creatine kinase levels 24-hours after a
90-min run [14]; however, none of the studies showed an
effect on cortisol response, establishing the effective dose
at 800 mg S-PS per day for short-term application (10–15
days). A recent study reported positive effects on emo-
tional response to a mental and emotional stressor after
the supplementation of a soy lecithin complex. 400 mg
per day resulted in a pronounced blunting of serum ACTH
and cortisol levels compared to placebo; yet, higher doses
(600 mg and 800 mg) did not result in the same effects
[15].
The purpose of the current study was to investigate the
efficacy of short-term S-PS supplementation, at dosage
levels less than the currently established dose, on cortisol,
testosterone, lactate, and growth hormone response to
acute moderate-intensity exercise.
Methods
Subjects
Ten healthy males participated in this study. All subjects
in this investigation participated in a familiarization ses-
sion. During the familiarization session, subjects were
informed as to the experimental procedures, completed a
personal/medical history form, and signed informed con-
sent statements in adherence with the human subject's
guidelines of the American College of Sports Medicine.
The study was approved by the Ethical Review Committee
of the University of Mississippi. Subject characteristics are
presented in table 1. No subject in this trial was a vegetar-
ian with all subjects reportedly consuming meat in their
daily diet.
Experimental Design
Each participant completed three testing sessions during
the 21-day study. Participants performed a graded exercise
test (starting at 50 W, increasing by 50 W increments every
2 minutes) on a cycle ergometer (Gary Fisher Tarpon OS
Series Mountain Bike connected to a Computrainer Pro
model 8002 RacerMate EBRA™ Approved System with
software version 1.1.59) to assess maximal oxygen con-
sumption (VO2 max), and were scheduled for testing ses-
sions 2 and 3 (day 11 and day 21). VO2 max was
determined using a Sensormedic V229 Metabolic System
that was calibrated following the recommended technical
guidelines (Sensormedics Corporation, Yorba Linda, CA).
Upon completion of the VO2 max test the participants were
randomly assigned to one of two groups and received a
10-day supply of either the placebo or PS (600 mg per day
of soy-derived PS).
Table 1: Subject characteristics (values are mean ± SEM).
Characteristic N = 10
Age (years) 26.2 ± 1.5
Bodyweight (kg) 89.3 ± 4.7
Height (cm) 176.8 ± 2.7
Peak VO2 max (ml/kg/min) 29.0 ± 2.2Journal of the International Society of Sports Nutrition 2008, 5:11 http://www.jissn.com/content/5/1/11
Page 3 of 6
(page number not for citation purposes)
The second and third exercise sessions were performed to
determine cortisol, growth hormone, and testosterone
responses to exercise-induced stress at rest, during exer-
cise, and recovery. On the tenth day of supplementation
the participants ingested the last dose of the assigned sub-
stance (PS or placebo) and reported to the laboratory at 7
am after an overnight fast. Venous blood samples were
taken on arrival (-30) and 30 minutes later, which was just
prior to the start of exercise (0). Following the 30 minute
rest period, the participants were asked to begin exercising
on the cycle ergometer at an exercise intensity calculated
to elicit 65% of VO2 max. The intensity of exercise was
increased automatically by 5% every 3-minute increment
until the intensity was at 85% of VO2 max (five-three
minute stages). After cycling for a total of 15 minutes, the
subject stopped exercising and a post-exercise venous
blood sample was taken immediately. The participant was
then moved to an examination table during the remaining
65 minutes of the recovery phase and venous blood sam-
ples were taken at 5, 15, 25, 45 and 65 minutes post-exer-
cise (+20, +30, +40, +60, +80). During the rest, exercise,
and recovery portion of the study the participant was
allowed to intake water ad libitum. Upon completion of
the first experimental session the participant was given the
other supplement treatment and repeated the previously
described protocol 10 days later.
The PS and placebo (maltodextrin) supplements were
administered in the form of chocolate flavored chewable
tablets that were obtained from SwissCo Development AG
(Sisseln, Switzerland). The subjects received a 10-day sup-
ply of each supplement after completing the VO2 max test
and the second exercise session.
Blood Analysis
The serial blood samples were taken from an antecubital
vein and collected into 10 ml tubes containing lithium
heparin, subsequently centrifuged and the plasma was
harvested. Separate aliquots of plasma (~500 μl) were
stored frozen at -80°C prior to analysis for cortisol, lac-
tate, and GH and free testosterone. Plasma concentrations
of cortisol and testosterone were analyzed in duplicate via
enzyme immunoassay (EIA) and GH concentrations were
analyzed in duplicate via enzyme-linked immunosorbant
assay (ELISA) using commercial available kits (Diagnostic
Systems Laboratories, Inc., Webster, TX). The YSI 1500
SPORT Lactate Analyzer (YSI Incorporated, Yellow
Springs, OH) was used to measure plasma lactate concen-
trations in duplicate.
Statistical Analysis
The statistical package used to analyze assay data results
was SPSS software version 10.0 for Windows (SPSS Inc.,
Chicago, IL). The sample size was based on the cortisol
response using an effect size of 1.0, an alpha level of 0.05,
and a power of .80. The determination of the sample size
and effect size was appropriate for the number of treat-
ments in this type of research and was consistent with
research conducted by Monteleone et al. [9], Fahey and
Pearl [10] and Hinkle et al. [16]. Pre- and post-supple-
mentation test measures were assessed for cortisol, testo-
sterone, lactate, growth hormone using a two-way
univariate repeated measures analysis of variances
(ANOVA) for treatment (soy PS, placebo) by time (-30, 0,
15, 20, 30, 40, 60, & 80 minutes). In addition, the area
under the curve (AUC) was calculated via integral calculus
for testosterone and cortisol in order to determine total
response and T/C ratio. A Student's paired t-test was per-
formed on the AUC and T/C ratio.
Results
Figure 1 shows the effects of S-PS or placebo supplemen-
tation on cortisol, testosterone, lactate and growth hor-
mone response to exercise-induced stress at -30, 0, 15, 20,
30, 40, 60, and 80 minutes after exercise. Mean peak con-
centrations are shown in table 2.
S-PS supplementation resulted in significant lower
plasma cortisol levels at the beginning of the exercise (p =
0.002) when compared to placebo. Differences for testo-
sterone (p = 0.20) and growth hormone levels (p = 0.30)
were not significant.
S-PS supplementation reduced plasma cortisol concentra-
tions by 39 ± 1% when compared with placebo (treatment
effect: F = 6.7, p = 0.03; treatment × time interaction effect:
F = 8.3, p = 0.05). Plasma testosterone concentrations
increased with S-PS (51 ± 6%) when compared with pla-
cebo; however, differences between groups failed to reach
statistical significance for the effect of treatment (F = 2.79,
p = 0.13) and treatment × time interaction effect (F = 0.35,
p = 0.87). Exercise resulted in an increase in lactate levels
in both groups, however, the increase failed to reach sta-
tistical significance (time effect: F = 5.41, p = 0.06). Sup-
plementation did not result in significant differences in
lactate response between the S-PS and placebo groups
(treatment effect: F = 0.47, p = 0.51; treatment × time
effect: F = 1.62, p = 0.34). Similarly, supplementation did
not influence plasma growth hormone concentrations
(treatment effect: F = 2.49, p = 0.15) or the pattern of
response (treatment × time interaction effect: F = 0.75, p =
0.66).
S-PS supplementation resulted in a favorable physiologi-
cal state when compared to the placebo group. Area under
the curve analysis (figure 2) showed significant differences
between S-PS and placebo for cortisol (35 ± 0% reduction,
p < 0.01), testosterone (37 ± 5% increase, p = 0.02), and
testosterone to cortisol ratio (184 ± 5% increase, p = 0.02,
figure 2).Journal of the International Society of Sports Nutrition 2008, 5:11 http://www.jissn.com/content/5/1/11
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Discussion
Supplementation with 600 mg of S-PS per day for 10 days
blunted cortisol response before and during exercise-
induced stress. Activation of the hypothalamo-pituitary-
adrenal (HPA) axis has been proposed as the mechanism
by which PS blunts cortisol production. The current theo-
ries assert that this may be accomplished by possibly alter-
ing receptor ligands interactions or corticotrophin
releasing factor (CRF) receptor interactions [17-20]. By
decreasing CRF there would be a decrease in ACTH,
thereby decreasing cortisol secretion. It has been proposed
the result of chronic treatment with PS alters CRF receptor
interactions resulting in reduced activation of the HPA
axis after stress [9]. Another possibility is that acute exer-
cise-induced stress influences the secretagogue arginine
vasopressin (AVP). Exercise of duration shorter than 15
minutes and intensities that exceed 65% of peak VO2 max
have been demonstrated to influence AVP to a greater
degree [21,22]. Therefore, a 600 mg per day dose of PS
may also inhibit the release of AVP, which would decrease
ACTH and subsequently cortisol.
Cortisol, testosterone, lactate and growth hormone response to exercise after 10 days of oral treatment with 600 mg S-PS or  placebo (pre-exercise phase -30 to 0 minutes, exercise phase: 0 to 15 minutes, recovery phase 16 to 80 minutes) Figure 1
Cortisol, testosterone, lactate and growth hormone response to exercise after 10 days of oral treatment with 
600 mg S-PS or placebo (pre-exercise phase -30 to 0 minutes, exercise phase: 0 to 15 minutes, recovery phase 
16 to 80 minutes).
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Table 2: Mean peak concentrations (mean ± SEM).
PS Placebo P value
 (treatment)
GH (ng/ml) 0.2 ± 0.0 0.3 ± 0.1 0.15
Testosterone (ng/ml) 8.3 ± 1.7 5.5 ± 0.3 0.13
Cortisol (μg/dl)* 26.9 ± 6.5 44.2 ± 12.7 0.03
Lactate (mmol/l) 4.3 ± 0.4 4.1 ± 0.4 0.51
T/C ratio 3.2 ± 3.2 1.6 ± 0.3 0.30
* represents significant difference (p < 0.05) between groupsJournal of the International Society of Sports Nutrition 2008, 5:11 http://www.jissn.com/content/5/1/11
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While S-PS supplementation resulted in lower cortisol
responses than placebo, it was associated with higher tes-
tosterone levels which were within the normal range of 3–
10 ng/ml for male subjects. The results of this study sup-
port evidence from previous research that high cortisol
levels impair male biosynthesis of testosterone in the tes-
tes, which might help explain why AUC for plasma testo-
sterone was higher following supplementation with S-PS
when compared to placebo [23,24]. As S-PS supplementa-
tion increased the AUC for testosterone and decreased the
AUC for cortisol, supplementation caused a significant
positive impact on the T/C ratio of the participants. A
reduction in the T/C ratio has been reported to indicate a
state of overtraining or negative state, whereas an eleva-
tion in the T/C ratio appears to indicate a more positive
state [7,25]. The S-PS phase had cortisol AUC levels that
were significantly lower than the placebo phase. Conse-
quently, S-PS supplementation gave rise to what could be
considered a positive physiological state [15]. The results
of this study suggest that 600 mg/d of S-PS might have the
potential to avert an overtrained state.
Not all research supports these conclusions. In a recent
investigation observing the effects of S-PS on oxidative
stress following intermittent running, the cortisol
response was not attenuated [13]. The key differences
between this investigation and previous studies are the
intensity of exercise and daily dose used during supple-
mentation. Previous studies utilized stress levels up to an
85% peak VO2 max while this study stressed the individuals
to exhaustion [13]. This suggests that phosphatidylserine
administration may have a rate-limited effect that is
dependent upon the intensity level which indicates that
the effect is based on a nutritional improvement rather
than a pharmacological effect. Phosphatidylserine has
been shown to improve enzymatic activity [26] by
improving membrane fluidity and composition [27]. PS
plays a significant role in the maintenance of neuronal
excitability and message transfer potentially resulting in a
reduced need for adrenergic stimulation at moderate
intensity exercise levels.
The GH and lactate results of this study are consistent with
findings in previous literature [9,10]. Growth hormone
responses varied little and were not significantly different
between the S-PS and the placebo phase. This suggests the
mechanism that influences the dynamics of the hypoth-
almo-pituitary axis with regards to GH release appear to
be unaffected by PS administration. Exercise caused
increases in plasma lactate concentrations during both tri-
als and supplementation did not influence these concen-
trations; therefore, the participants exercised at similar
workloads during both phases of the study.
The potential of PS as an alternative nutritional strategy
for disorders that are associated with cortisol over-produc-
tion has not been investigated, suggesting that there is a
need for further research in the use of PS as a potential aid
for overtraining and as an aid in exercise related activities.
Furthermore, this study, along with previous literature,
demonstrates that PS can influence neuroendocrine func-
tion; consequently, the possibility exists that PS might be
a beneficial nutrient in conditions such as obesity and
type 2 diabetes.
Conclusion
PS supplementation with 600 mg per day for 10 days
blunts the cortisol response to exercise-induced stress. In
addition, PS significantly increases the testosterone to cor-
tisol ratio. These findings suggest that PS is an effective
supplement for combating exercise-induced stress. PS
supplementation promotes a desirable hormonal balance
S-PS significantly decreased cortisol (35 ± 0%, p < 0.01) and increased testosterone (37 ± 5%, p = 0.02) AUC levels and testo- sterone to cortisol ratio (184 ± 5%, p = 0.02) in comparison to placebo Figure 2
S-PS significantly decreased cortisol (35 ± 0%, p < 0.01) and increased testosterone (37 ± 5%, p = 0.02) AUC lev-
els and testosterone to cortisol ratio (184 ± 5%, p = 0.02) in comparison to placebo.
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for athletes and might attenuate the physiological deteri-
oration that accompanies overtraining and/or overstretch-
ing.
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